Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium

被引:10
作者
Bernstein, Cheryl D. [1 ]
Albrecht, Kara L. [1 ]
Marcus, Dawn A. [2 ]
机构
[1] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15206 USA
[2] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15237 USA
关键词
antidepressant; depression; fatigue; serotonin-norepinephrine reuptake inhibitor; weight loss; NORADRENALINE REUPTAKE INHIBITOR; DOUBLE-BLIND; THERAPEUTIC RESPONSE; CLINICAL-TRIAL; RAT MODEL; SEROTONIN; PLACEBO; ANTIDEPRESSANTS; PAIN; PREGABALIN;
D O I
10.1517/14656566.2013.779670
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Antidepressants are used to treat a variety of chronic pain conditions including peripheral neuropathy, headache, and more recently, fibromyalgia. The antidepressant milnacipran blocks the reuptake of norepinephrine and serotonin and is used for the management of fibromyalgia. Areas covered: The article contains data primarily obtained from the MEDLINE database using a PubMed search of the keywords including milnacipran, fibromyalgia and depression. Of the available serotonin norepinephrine reuptake inhibitors, milnacipran has greater potency in inhibiting reuptake of norepinephrine relative to serotonin and is proposed to work by attenuating pain signals. Milnacipran is well tolerated and effective for fibromyalgia pain when given in divided doses of 100 - 200 mg daily. Studies show that milnacipran may be effective for fibromyalgia-associated symptoms including depression and fatigue. Expert opinion: Milnacipran provides modest fibromyalgia pain relief and is best used as part of a multidisciplinary treatment approach. While milnacipran was not studied in fibromyalgia patients with major depression, it may be a wise choice for fibromyalgia patients with depressive symptoms and patients for whom sedation, dizziness, edema or weight gain with gabapentin and pregabalin is a problem. Milnacipran has been found to be beneficial for treating some troublesome fibromyalgia-associated symptoms, including fatigue and cognitive dysfunction.
引用
收藏
页码:905 / 916
页数:12
相关论文
共 82 条
[51]  
Miller Adam, 2005, Psychiatr Pol, V39, P21
[52]   Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats [J].
Mochizuki, D ;
Tsujita, R ;
Yamada, S ;
Kawasaki, K ;
Otsuka, Y ;
Hashimoto, S ;
Hattori, T ;
Kitamura, Y ;
Miki, N .
PSYCHOPHARMACOLOGY, 2002, 162 (03) :323-332
[53]   Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons [J].
Mongeau, R ;
Weiss, M ;
de Montigny, C ;
Blier, P .
NEUROPHARMACOLOGY, 1998, 37 (07) :905-918
[54]  
Moret C, 1997, J NEUROCHEM, V69, P815
[55]   An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat [J].
Nakajima, Kunie ;
Obata, Hideaki ;
Iriuchijima, Nobuhisa ;
Saito, Shigeru .
PAIN, 2012, 153 (05) :990-997
[56]   Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants [J].
Nishiyori, Michiko ;
Uchida, Hitoshi ;
Nagai, Jun ;
Araki, Kohei ;
Mukae, Takehiro ;
Kishioka, Shiroh ;
Ueda, Hiroshi .
MOLECULAR PAIN, 2011, 7
[57]  
Nuesch E, 2012, ANN RHEUM D IN PRESS
[58]   Treatment of fibromyalgia with antidepressants - A meta-analysis [J].
O'Malley, PG ;
Balden, E ;
Tomkins, G ;
Santoro, J ;
Kroenke, K ;
Jackson, JL .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2000, 15 (09) :659-666
[59]   The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain [J].
Obata, H ;
Saito, S ;
Koizuka, S ;
Nishikawa, K ;
Goto, F .
ANESTHESIA AND ANALGESIA, 2005, 100 (05) :1406-1410
[60]   Effects of milnacipran, a 5-HT and noradrenaline reuptake inhibitor, on C-fibre-evoked field potentials in spinal long-term potentiation and neuropathic pain [J].
Ohnami, S. ;
Kato, A. ;
Ogawa, K. ;
Shinohara, S. ;
Ono, H. ;
Tanabe, M. .
BRITISH JOURNAL OF PHARMACOLOGY, 2012, 167 (03) :537-547